BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20195170)

  • 1. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy.
    Sun JM; Park JO; Won YW; Kim JH; Yun J; Lee J; Park YH; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2010 Apr; 5(4):540-5. PubMed ID: 20195170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
    Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
    Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
    Tong KM; Laskin J; Ho C
    Lung Cancer; 2015 Mar; 87(3):296-302. PubMed ID: 25601487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L; Sørensen JB
    Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-line therapy in advanced non-small cell lung cancer.
    Ying Geng Z; Chang Jiao S; Cui Liu S; Li Y; Feng Liu Z; Qing Zhang G; Jie Wang L; Qu F
    J BUON; 2013; 18(4):899-907. PubMed ID: 24344015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer.
    Tatli AM; Arslan D; Uysal M; Goksu SS; Gunduz SG; Coskun HS; Ozdogan M; Savas B; Bozcuk HS
    J Cancer Res Ther; 2015; 11(4):805-9. PubMed ID: 26881522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
    Sacher AG; Le LW; Lau A; Earle CC; Leighl NB
    Cancer; 2015 Aug; 121(15):2562-9. PubMed ID: 25891153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
    Kosmidis PA; Syrigos K; Kalofonos HP; Dimopoulos MA; Skarlos D; Pavlidis N; Boukovinas I; Bafaloukos D; Pectasides D; Bacoyiannis C; Fountzilas G
    Anticancer Res; 2012 Jan; 32(1):175-81. PubMed ID: 22213304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Paclitaxel-bevacizumab is a possible alternative as salvage chemotherapy in advanced non-small cell bronchial carcinoma].
    Zarza V; Couraud S; Bosc C; Toffart AC; Moro-Sibilot D; Souquet PJ
    Rev Mal Respir; 2014 Sep; 31(7):601-7. PubMed ID: 25239581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.
    Hensing TA; Schell MJ; Lee JH; Socinski MA
    Lung Cancer; 2005 Feb; 47(2):253-9. PubMed ID: 15639724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
    Wakelee HA; Bernardo P; Johnson DH; Schiller JH
    Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
    Lin CM; Chen CH; Chang JW; Tsao TC
    Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
    Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
    Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with long-term survival of patients with advanced non-small cell lung cancer.
    Giroux Leprieur E; Lavole A; Ruppert AM; Gounant V; Wislez M; Cadranel J; Milleron B
    Respirology; 2012 Jan; 17(1):134-42. PubMed ID: 21943088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: a retrospective study.
    Kim JH; Kim HS; Kwon JH; Park S; Kim HY; Jung JY; Kim HJ; Song HH; Lee GW; Lee SI; Gong SJ; Lee JA; Kim KJ; Zang DY
    Lung Cancer; 2009 Mar; 63(3):405-9. PubMed ID: 18621432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.